Carousel

Chimeric Antigen Receptor T-cells (CAR-T cells)

Arming T-cells to target and kill cancer cells

A central player in cancer immunotherapies is a type of white blood cell known as the T‑cell which is equipped with cell killing mechanisms. In healthy subjects, T‑cells identify and kill infected or abnormal cells, including cancer cells. A Chimeric Antigen Receptor (CAR) is engineered by inserting, in the DNA of a T‑cell, a sequence that will push the T‑cell to express an antibody designed to recognize and bind a specific antigen present on the cancer cell. Once the antibody/antigen binding has occurred, the T‑cell will destroy the targeted cancer cells. To make a CAR effective in killing cancer, a signaling protein is added to the construct, to trigger cell killing by the CAR-T cell. In an attempt to render the CAR‑T cells more potent, researchers have added other proteins in its construct, called co-stimulatory molecules, which are in charge of helping CAR‑T cells survive for a longer period of time and multiply in the body. Current clinical research in the CAR‑T field showed very encouraging results in cancer patients suffering from blood cancers (ex : CD19).

Latest News

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad announces initiation of the SHRINK trial

Celyad announces initiation of the SHRINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Celyad publishes additional pre-clinical data in support of THINK trial

Discover all news

Technology developed at Celyad

Want to see more?

Technology developed at Celyad